Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer, Single-arm, Exploratory Clinical Study

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Fluorouracil (Primary) ; Paclitaxel (Primary) ; Tislelizumab (Primary)
Indications Adenocarcinoma; Gastric cancer
Focus Therapeutic Use

18 Jun 2023 Planned End Date changed from 1 Mar 2025 to 1 Jun 2025.
18 Jun 2023 Planned primary completion date changed from 28 Feb 2024 to 1 Jun 2024.
18 Jun 2023 Planned initiation date changed from 28 Feb 2023 to 1 Jul 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com